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1. INTRODUCTION {#cam41967-sec-0005}
===============

Pancreatic adenocarcinoma, the fourth leading cause of cancer death in the United States, is a treatment challenge with a dismal median survival of 12.4 months.[1](#cam41967-bib-0001){ref-type="ref"} Surgical resection is considered the only potentially curative approach, though survival rates are modest, with a 5‐year overall survival (OS) of 7%‐17%.[2](#cam41967-bib-0002){ref-type="ref"}, [3](#cam41967-bib-0003){ref-type="ref"}, [4](#cam41967-bib-0004){ref-type="ref"} With local failure rates as high as 73% after surgery,[2](#cam41967-bib-0002){ref-type="ref"}, [3](#cam41967-bib-0003){ref-type="ref"}, [4](#cam41967-bib-0004){ref-type="ref"} various adjuvant therapies, including chemoradiation (CRT), have been investigated in clinical trials and institutional studies as a means to address the poor clinical outcomes in patients with pancreatic adenocarcinoma. Several reports have demonstrated improved OS with the use of adjuvant chemoradiation, with median OS times ranging from 19.5 to 25.2 months.[5](#cam41967-bib-0005){ref-type="ref"}, [6](#cam41967-bib-0006){ref-type="ref"}, [7](#cam41967-bib-0007){ref-type="ref"}, [8](#cam41967-bib-0008){ref-type="ref"}, [9](#cam41967-bib-0009){ref-type="ref"} Several National Cancer Database (NCDB) studies have similarly shown improved OS with adjuvant CRT.[10](#cam41967-bib-0010){ref-type="ref"}, [11](#cam41967-bib-0011){ref-type="ref"}, [12](#cam41967-bib-0012){ref-type="ref"}

Literature for the role of chemotherapy (C) before CRT for resected pancreatic adenocarcinoma is limited. A phase III study of adjuvant fluorouracil vs gemcitabine, given for 3 weeks followed by CRT, and then an additional 3 months of C, found no difference in OS with either agent.[13](#cam41967-bib-0013){ref-type="ref"} A NCDB analysis, did however, report a survival benefit with chemotherapy prior to CRT for locally advanced pancreatic cancer.[14](#cam41967-bib-0014){ref-type="ref"} Due to a lack of comparative studies, the value of C prior to CRT specifically for early‐stage pancreatic cancer remains unclear.

This study compares the outcomes of patients who received C + CRT vs those who received C or CRT alone for stage I‐II, resected pancreatic cancer.

2. METHODS {#cam41967-sec-0006}
==========

2.1. Patient population {#cam41967-sec-0007}
-----------------------

The NCDB registry was used to identify patients with pancreatic adenocarcinoma diagnosed between 2004 and 2015 (the most recent dataset available at the time of this study). The NCDB is a nationwide cancer database that captures approximately 70% of newly diagnosed cancer cases in the United States and includes 34 million historical records.[15](#cam41967-bib-0015){ref-type="ref"} It provides access to de‐identified datasets from Commission on Cancer‐accredited programs through online application. This study was exempt from institutional review board review.

Our patient selection criteria are shown in Figure [1](#cam41967-fig-0001){ref-type="fig"}. We selected from our initial query of patients with stage I‐II, clinical T1‐3N0‐1M0 pancreatic adenocarcinoma who had been treated with curative‐intent resection followed by adjuvant chemotherapy and conventionally fractionated radiation therapy. American Joint Committee on Cancer (AJCC) 6th and 7th editions were used to determine stage I‐II disease in 2004‐2015.

![CONSORT diagram for patient selection criteria](CAM4-8-939-g001){#cam41967-fig-0001}

Whipple surgery was defined as local or partial pancreatectomy and duodenectomy with partial gastrectomy. Whipple‐variant surgery was characterized as partial pancreatectomy with duodenectomy, total pancreatectomy alone, or total pancreatectomy with subtotal gastrectomy or duodenectomy.[16](#cam41967-bib-0016){ref-type="ref"} Patients treated with chemotherapy or radiation therapy within 30 days of each other were considered to have received adjuvant CRT alone. Those who were treated with adjuvant chemotherapy within 31‐180 days prior to the radiation therapy were defined as having received C + CRT.[14](#cam41967-bib-0014){ref-type="ref"} Patients who received adjuvant chemotherapy more than 180 days prior to adjuvant radiation therapy were excluded.

Patients were excluded if they had incomplete follow‐up data, missing radiation dose or fractionation information, incomplete data on the number of days between diagnosis and treatments, or missing information regarding surgical margins. Patients treated with palliative‐intent or with neoadjuvant chemotherapy or radiation were also excluded. To address immortal time bias, those with postdiagnosis survival duration of \<3 months were not included.[17](#cam41967-bib-0017){ref-type="ref"}

Baseline patient, tumor, and treatment characteristics for analysis included the following: facility type, age, gender, race, insurance type, income level, residential setting, Charlson‐Deyo comorbidity score (CDS), year of diagnosis, primary tumor location within pancreas, tumor grade, tumor size, clinical T and N stages, pathologic T and N stages, number of biopsy‐positive lymph nodes, surgery type, surgical margin, total radiation dose, and chemotherapy use. Surgical margin was categorized as either negative (R0) or positive (R1, R2, positive margin not otherwise specified). Patients were stratified by age ≥66 or \<66 years, and tumor size \<3.1 or ≥3.1 cm based on their median values. The household income level of each patient\'s residential area was based on the 2012 American Community Survey data adjusted for inflation (the most recent data at the time of this study) and was stratified above or below the median value of \$48 000. CA 19‐9 factor was coded by the NCDB with a cut off of \<98 or ≥98 Units/mL, although CA 19‐9 was not used for propensity score matching due to missing data in 3064 (54.1%) of patients. Local and distant failure/progression information is also unable to be analyzed based on data from the NCDB. Important prognostic variables such as the patient\'s initial performance status, type and duration of chemotherapy received, and toxicity outcomes are unavailable in the NCDB. The primary endpoint was overall survival (OS), time between the diagnosis and the last follow‐up or death.

2.2. Statistical analysis {#cam41967-sec-0008}
-------------------------

OS was evaluated using the Kaplan‐Meier method and log‐rank tests. Fisher\'s exact test and Mann‐Whitney *U* test were used to compare categorical and continuous variables between two treatment cohorts, respectively. Logistic regression univariable (UVA) and multivariable analyses (MVA) were used to determine potential factors that predicted the use of postoperative chemotherapy and were reported as odds ratio (OR). Cox proportional hazard UVA and MVA were used to determine factors that predict the OS and were reported as hazards ratio (HR). MVA was initially constructed using all statistically significant variables from UVA and was finalized using a backward stepwise elimination. Only patients with complete information on such variables were included. Potential interactions between the treatment and other covariates were examined using Cox MVA by adding interaction terms.[18](#cam41967-bib-0018){ref-type="ref"} When the interaction terms were statistically significant, the final Cox MVA model was re‐analyzed for each subgroup of covariates, and a forest plot was constructed to illustrate the direction and magnitude of treatment effects.[18](#cam41967-bib-0018){ref-type="ref"}

To minimize selection bias, propensity score matching was used. Match‐pairs were constructed by matching baseline patient, tumor, and treatment characteristics. Variables of interest include facility type, year of diagnosis, age, CDS, tumor grade, tumor size, surgery type, chemotherapy use, total radiation dose, pathologic T and N stages, and additional variables that were statistically significant in Cox proportional hazard MVA results for each cohort. All matching was performed in a 1:1 ratio without any replacement and was based on nearest neighbor method with a caliper distance of 0.2 of the standard deviation of the logit of the propensity score.[19](#cam41967-bib-0019){ref-type="ref"} Matching was performed using MatchIt package (version 3.0.1). R software (version 3.5.0, R Foundation for Statistical Computing, Vienna, Austria) was used for all aforementioned analyses. All *P* values were two‐sided. A *P* value \<0.05 was considered statistically significant.

3. RESULTS {#cam41967-sec-0009}
==========

A total of 5667 patients with resected clinical stage I‐II, T1‐3N0‐1M0 pancreatic adenocarcinoma were identified for analysis. Of those, adjuvant C, CRT, and C + CRT were delivered to 3031, 1307, and 1329 patients, respectively. Overall follow‐up was 37.4 months (IQR \[interquartile range\] 24.5‐59.3). The majority of patients had pathologic T3N1 adenocarcinoma of the pancreatic head with negative surgical margins (Tables [1](#cam41967-tbl-0001){ref-type="table"} and [2](#cam41967-tbl-0002){ref-type="table"}). Of the 2636 (1307 + 1329) patients who received RT, 2050 (1001 for CRT, 1049 for C + CRT) patients received RT to the pancreas, and 420 (221 for CRT, 199 for C + CRT) patients received RT to the abdomen (not otherwise specified); therefore, 93.7% (2470/2636) of patients received RT to the pancreas or abdomen. A total of 107 (107/1307 = 8.2%) and 106 (106/1329 = 8.0%) patients received \<45 Gy in cohort CRT and C + CRT, respectively.

###### 

Baseline characteristics for cohort C

                                   Before matching   After matching                                                       
  -------------------------------- ----------------- ---------------- ----------- ---- --------- ------ ----- ------ ---- -------
  Facility                                                                                                                
  Nonacademic                      1454              48               789         59   \<0.001   622    58    631    59   0.73
  Academic                         1557              51               521         39   454       42     445   41          
  NA                               20                1                19          1    0         0      0     0           
  Age                                                                                                                     
  \<66                             1297              43               762         57   \<0.001   620    58    589    55   0.19
  ≥66                              1734              57               567         43   456       42     487   45          
  NA                               0                 0                0           0    0         0      0     0           
  Gender                                                                                                                  
  Female                           1497              49               663         50   0.77                               
  Male                             1534              51               666         50                                      
  NA                               0                 0                0           0                                       
  Race                                                                                                                    
  White                            2645              87               1148        86   0.60                               
  Black                            270               9                121         9                                       
  Other                            95                3                49          4                                       
  NA                               21                1                11          1                                       
  Insurance                                                                                                               
  None                             70                2                34          3    \<0.001                            
  Nonprivate                       1846              61               684         51                                      
  Private                          1096              36               601         45                                      
  NA                               19                1                10          1                                       
  Income                                                                                                                  
  Above median                     1947              64               870         65   0.37      704    65    707    66   0.93
  Below median                     1053              35               441         33   372       35     369   34          
  NA                               31                1                18          1    0         0      0     0           
  Residential setting                                                                                                     
  Metro                            2470              81               1086        82   0.84                               
  Urban                            410               14               181         14                                      
  Rural                            49                2                18          1                                       
  NA                               102               3                44          3                                       
  Charlson‐Deyo Score                                                                                                     
  0‐1                              2805              93               1248        94   0.11      1011   94    1008   94   0.86
  ≥2                               226               7                81          6    65        6      68    6           
  NA                               0                 0                0           0    0         0      0     0           
  Year of diagnosis                                                                                                       
  2004‐2007                        195               6                74          6    \<0.001   62     6     46     4    0.13
  2008‐2011                        1376              45               696         52   506       47     543   50          
  2012‐2015                        1460              48               559         42   508       47     487   45          
  NA                               0                 0                0           0    0         0      0     0           
  Primary tumor site                                                                                                      
  Head                             2391              79               1105        83   \<0.001                            
  Body                             237               8                105         8                                       
  Tail                             403               13               119         9                                       
  NA                               0                 0                0           0                                       
  Tumor grade                                                                                                             
  Well diff                        202               7                112         8    0.024     78     7     91     8    0.083
  Mod diff                         1450              48               652         49   559       52     566   53          
  Poor diff                        1126              37               448         34   431       40     400   37          
  Other                            30                1                20          2    8         1      19    2           
  NA                               223               7                97          7    0         0      0     0           
  Tumor size (cm)                                                                                                         
  \<3.1                            1466              48               657         49   0.35      526    49    526    49   1
  ≥3.1                             1511              50               636         48   550       51     550   51          
  NA                               54                2                36          3    0         0      0     0           
  Clinical T stage                                                                                                        
  1                                505               17               195         15   0.15                               
  2                                1180              39               509         38                                      
  3                                1346              44               625         47                                      
  NA                               0                 0                0           0                                       
  Clinical N stage                                                                                                        
  0                                2122              70               871         66   0.0036                             
  1                                909               30               458         34                                      
  NA                               0                 0                0           0                                       
  Pathologic T stage                                                                                                      
  0                                1                 0                1           0    0.013     0      0     1      0    0.81
  1                                158               5                45          3    41        4      37    3           
  2                                404               13               153         12   110       10     123   11          
  3                                2299              76               1056        79   908       84     898   83          
  4                                38                1                22          2    17        2      17    2           
  Other                            1                 0                0           0    0         0      0     0           
  NA                               130               4                52          4    0         0      0     0           
  Pathologic N stage                                                                                                      
  0                                900               30               293         22   \<0.001   257    24    256    24   1
  1                                1988              66               971         73   819       76     820   76          
  NA                               143               5                65          5    0         0      0     0           
  Number of positive lymph nodes                                                                                          
  0                                920               30               297         22   \<0.001                            
  1‐3                              1173              39               585         44                                      
  4+                               848               28               415         31                                      
  NA                               90                3                32          2                                       
  Surgery                                                                                                                 
  Whipple variant                  941               31               397         30   0.33      364    34    325    30   0.079
  Whipple                          1409              46               650         49   477       44     528   49          
  Other                            681               22               282         21   235       22     223   21          
  NA                               0                 0                0           0    0         0      0     0           
  Surgical margin                                                                                                         
  Negative                         2429              80               968         73   \<0.001   826    77    807    75   0.36
  Positive                         510               17               336         25   250       23     269   25          
  NA                               92                3                25          2    0         0      0     0           
  Chemotherapy                                                                                                            
  Single agent                     2376              78               766         58   \<0.001   650    60    634    59   0.51
  Multi agent                      655               22               563         42   426       40     442   41          
  NA                               0                 0                0           0    0         0      0     0           
  Radiation dose (Gy)                                                                                                     
  Median                           ---                                50.4             NA                                 
  IQR                              ---                                50.0‐50.4                                           

C, chemotherapy; CRT, chemoradiation; diff, differentiated; IQR, interquartile range; mod, moderately; NA, not available; poor, poorly.

John Wiley & Sons, Ltd

###### 

Baseline characteristics for cohort CRT

                                   Before matching   After matching                                                              
  -------------------------------- ----------------- ---------------- ----------- ----------- --------- ------ ----- ------ ---- ------
  Facility                                                                                                                       
  Nonacademic                      848               65               789         59          0.0085    548    62    539    61   0.70
  Academic                         452               35               521         39          339       38     348   39          
  NA                               7                 1                19          1           0         0      0     0           
  Age                                                                                                                            
  \<66                             674               52               762         57          0.0030    472    53    498    56   0.23
  ≥66                              633               48               567         43          415       47     389   44          
  NA                               0                 0                0           0           0         0      0     0           
  Gender                                                                                                                         
  Female                           645               49               663         50          0.79                               
  Male                             662               51               666         50                                             
  NA                               0                 0                0           0                                              
  Race                                                                                                                           
  White                            1141              87               1148        86          0.19                               
  Black                            119               9                121         9                                              
  Other                            32                2                49          4                                              
  NA                               15                1                11          1                                              
  Insurance                                                                                                                      
  None                             31                2                34          3           0.071                              
  Nonprivate                       728               56               684         51                                             
  Private                          533               41               601         45                                             
  NA                               15                1                10          1                                              
  Income                                                                                                                         
  Above median                     733               56               870         65          \<0.001   547    62    563    63   0.46
  Below median                     544               42               441         33          340       38     324   37          
  NA                               30                2                18          1           0         0      0     0           
  Residential setting                                                                                                            
  Metro                            1023              78               1086        82          0.049                              
  Urban                            201               15               181         14                                             
  Rural                            31                2                18          1                                              
  NA                               52                4                44          3                                              
  Charlson‐Deyo Score                                                                                                            
  0‐1                              1235              94               1248        94          0.56      836    94    841    95   0.68
  ≥2                               72                6                81          6           51        6      46    5           
  NA                               0                 0                0           0           0         0      0     0           
  Year of diagnosis                                                                                                              
  2004‐2007                        210               16               74          6           \<0.001   69     8     47     5    0.11
  2008‐2011                        680               52               696         52          458       52     467   53          
  2012‐2015                        417               32               559         42          360       41     373   42          
  NA                               0                 0                0           0           0         0      0     0           
  Primary tumor site                                                                                                             
  Head                             1076              82               1105        83          0.015                              
  Body                             78                6                105         8                                              
  Tail                             153               12               119         9                                              
  NA                               0                 0                0           0                                              
  Tumor grade                                                                                                                    
  Well diff                        108               8                112         8           0.64      75     8     79     9    0.13
  Mod diff                         629               48               652         49          460       52     478   54          
  Poor diff                        455               35               448         34          346       39     315   36          
  Other                            13                1                20          2           6         1      15    2           
  NA                               102               8                97          7           0         0      0     0           
  Tumor size (cm)                                                                                                                
  \<3.1                            575               44               657         49          0.0050    410    46    410    46   1
  ≥3.1                             697               53               636         48          477       54     477   54          
  NA                               35                3                36          3           0         0      0     0           
  Clinical T stage                                                                                                               
  1                                158               12               195         15          0.15                               
  2                                517               40               509         38                                             
  3                                632               48               625         47                                             
  NA                               0                 0                0           0                                              
  Clinical N stage                                                                                                               
  0                                874               67               871         66          0.48                               
  1                                433               33               458         34                                             
  NA                               0                 0                0           0                                              
  Pathologic T stage                                                                                                             
  0                                1                 0                1           0           0.61      1      0     1      0    0.95
  1                                49                4                45          3           30        3      36    4           
  2                                169               13               153         12          108       12     105   12          
  3                                980               75               1056        79          731       82     729   82          
  4                                22                2                22          2           17        2      16    2           
  Other                            0                 0                0           0           0         0      0     0           
  NA                               86                7                52          4           0         0      0     0           
  Pathologic N stage                                                                                                             
  0                                338               26               293         22          0.0075    228    26    226    25   0.96
  1                                874               67               971         73          659       74     661   75          
  NA                               95                7                65          5           0         0      0     0           
  Number of positive lymph nodes                                                                                                 
  0                                363               28               297         22          \<0.001                            
  1‐3                              585               45               585         44                                             
  4+                               324               25               415         31                                             
  NA                               35                3                32          2                                              
  Surgery                                                                                                                        
  Whipple variant                  342               26               397         30          0.10      253    29    256    29   0.98
  Whipple                          668               51               650         49          437       49     436   49          
  Other                            297               23               282         21          197       22     195   22          
  NA                               0                 0                0           0           0         0      0     0           
  Surgical margin                                                                                                                
  Negative                         891               68               968         73          0.012     643    72    637    72   0.79
  Positive                         386               30               336         25          244       28     250   28          
  NA                               30                2                25          2           0         0      0     0           
  Chemotherapy                                                                                                                   
  Single agent                     824               63               766         58          0.0047    536    60    515    58   0.33
  Multi agent                      483               37               563         42          351       40     372   42          
  NA                               0                 0                0           0           0         0      0     0           
  Radiation dose (Gy)                                                                                                            
  Median                           50.4                               50.4                    0.18      50.4         50.4        0.17
  IQR                              50.0‐54.0         50.0‐50.4        50.0‐54.0   50.0‐50.4                                      

C, chemotherapy; CRT, chemoradiation; diff, differentiated; IQR, interquartile range; mod, moderately; NA, not available; poor, poorly.

John Wiley & Sons, Ltd

On logistic MVA for all patients, patients with diagnosis between 2008 and 2011 (OR 2.17, *P* \< 0.001) and 2012 and 2015 (OR 1.99, *P* \< 0.001), pathologic nodal diseases (OR 1.37, *P* \< 0.001 for 1‐3 positive nodes; OR 1.32, *P* = 0.0034 for 4+ positive nodes), positive surgical margin (OR 1.25, *P* = 0.0062), and receipt of multiagent chemotherapy (OR 2.01, *P* \< 0.001) were more likely to receive C + CRT compared to C or CRT alone. Patients treated at academic facilities (OR 0.73, *P* \< 0.001), older than 66 years old (OR 0.66, *P* \< 0.001), from low‐income regions (OR 0.83, *P* = 0.0083), with pancreatic tail disease (OR 0.68, *P* = 0.0011), and poorly differentiated histology (OR 0.74, *P* = 0.019) were less likely to undergo C + CRT.

On Cox MVA for all patients (Table [3](#cam41967-tbl-0003){ref-type="table"}), those older than 66 years old (HR 1.14, *P* \< 0.001), from low‐income regions (HR 1.10, *P* = 0.0082), with higher CDS (HR 1.23, *P* = 0.0017), moderately (HR 1.18, *P* = 0.018) or poorly differentiated (HR 1.51, *P* \< 0.001) disease, tumors larger than 3.1 cm (HR 1.26, *P* \< 0.001), pathologic positive nodal diseases (HR 1.46, *P* \< 0.001 for 1‐3 positive nodes; HR 1.79, *P* \< 0.001 for 4+ positive nodes), high CA 19‐9 (≥98 U/mL) (HR 1.30, *P* \< 0.001), and positive surgical margins (HR 1.47, *P* \< 0.001) were associated with worse mortality. When compared to C + CRT, those treated with C (HR 1.31, *P* \< 0.001) or CRT alone (HR 1.24, *P* \< 0.001) had worse survival outcomes. Improved overall survival was observed in those treated at academic facilities (HR 0.83, *P* \< 0.001) and pathologic T1‐2 diseases (HR 0.87, *P* = 0.0051).

###### 

Cox UVA and MVA for all cohorts

  Variable                         Cox UVA   Cox MVA                                  
  -------------------------------- --------- ----------- --------- ------ ----------- ---------
  Facility                                                                            
  Nonacademic                      1         Ref                   1      Ref         
  Academic                         0.88      0.82‐0.93   \<0.001   0.83   0.78‐0.89   \<0.001
  Age                                                                                 
  \<66                             1         Ref                   1      Ref         
  ≥66                              1.16      1.09‐1.23   \<0.001   1.14   1.06‐1.22   \<0.001
  Gender                                                                              
  Female                           1         Ref                                      
  Male                             1.01      0.95‐1.08   0.64                         
  Race                                                                                
  White                            1         Ref                                      
  Black                            0.98      0.88‐1.10   0.76                         
  Other                            0.95      0.79‐1.14   0.55                         
  Insurance                                                                           
  None                             1         Ref                                      
  Nonprivate                       1.15      0.94‐1.42   0.18                         
  Private                          0.95      0.77‐1.17   0.64                         
  Income                                                                              
  Above median                     1         Ref                   1      Ref         
  Below median                     1.14      1.07‐1.21   \<0.001   1.10   1.02‐1.18   0.0082
  Residential setting                                                                 
  Metro                            1         Ref                   1      Ref         
  Urban                            1.08      0.99‐1.18   0.086                        
  Rural                            1.37      1.10‐1.71   0.0052    1.20   0.94‐1.53   0.15
  Charlson‐Deyo score                                                                 
  0‐1                              1         Ref                   1      Ref         
  ≥2                               1.2       1.06‐1.35   0.0033    1.23   1.08‐1.40   0.0017
  Year of diagnosis                                                                   
  2004‐2007                        1         Ref                                      
  2008‐2011                        0.97      0.88‐1.08   0.63                         
  2012‐2015                        0.90      0.80‐1.00   0.051                        
  Primary tumor site                                                                  
  Head                             1         Ref                                      
  Body                             0.92      0.81‐1.03   0.15                         
  Tail                             0.95      0.87‐1.05   0.33                         
  Tumor grade                                                                         
  Well diff                        1         Ref                   1      Ref         
  Mod diff                         1.22      1.07‐1.38   0.0022    1.18   1.03‐1.35   0.018
  Poor diff                        1.60      1.41‐1.82   \<0.001   1.51   1.32‐1.73   \<0.001
  Other                            1.19      0.86‐1.66   0.30                         
  Tumor size (cm)                                                                     
  \<3.1                            1         Ref                   1      Ref         
  ≥3.1                             1.42      1.34‐1.52   \<0.001   1.26   1.18‐1.35   \<0.001
  Pathologic T stage                                                                  
  0‐2                              1         Ref                   1      Ref         
  3‐4                              0.72      0.66‐0.79   \<0.001   0.87   0.79‐0.96   0.0051
  Number of positive lymph nodes                                                      
  0                                1         Ref                   1      Ref         
  1‐3                              1.61      1.48‐1.74   \<0.001   1.46   1.34‐1.59   \<0.001
  4+                               2.08      1.91‐2.27   \<0.001   1.79   1.63‐1.97   \<0.001
  Surgery                                                                             
  Whipple variant                  1         Ref                                      
  Whipple                          1.04      0.97‐1.12   0.30                         
  Other                            1.03      0.94‐1.12   0.51                         
  Surgical margin                                                                     
  Negative                         1         Ref                   1      Ref         
  Positive                         1.64      1.53‐1.76   \<0.001   1.47   1.36‐1.59   \<0.001
  Chemotherapy                                                                        
  Single agent                     1         Ref                                      
  Multi agent                      1.03      0.96‐1.10   0.47                         
  Radiation dose (Gy)                                                                 
  1 Gy increase                    1.00      1.00‐1.00   1                            
  Treatment                                                                           
  C + CRT                          1         Ref                   1      Ref         
  CRT                              1.19      1.09‐1.30   \<0.001   1.24   1.12‐1.37   \<0.001
  C                                1.15      1.07‐1.24   \<0.001   1.31   1.20‐1.43   \<0.001

CI, confidence interval; diff, differentiated; HR, hazard ratio; mod, moderately; MVA, multivariable analysis; poor, poorly; Ref, reference; UVA, univariate analysis.

John Wiley & Sons, Ltd

After Cox MVA, treatment interactions were observed in positive nodal disease subgroups (1‐3 positive nodes: HR 0.78, *P* = 0.020; 4+ positive nodes: HR 0.79, *P* = 0.041). No other treatment interactions were seen in age (HR 0.94, *P* = 0.46), CDS (HR 0.98, *P* = 0.88), years of diagnosis (2008‐2011: HR 1.05, *P* = 0.76; 2012‐2015: HR 1.05, *P* = 0.79), tumor size (HR 0.93, *P* = 0.40), surgical margin (HR 0.89, *P* = 0.23), or pathologic T stages (HR 1.10, *P* = 0.40). On subgroup analysis (Figure [2](#cam41967-fig-0002){ref-type="fig"}), nodal disease favored C + CRT when compared to C or CRT alone (0 positive node: HR 0.96, *P* = 0.67; 1‐3 positive nodes: HR 0.74, *P* \< 0.001; 4+ positive nodes: HR 0.75, *P* \< 0.001).

![Forest plot for subgroup analysis. C, adjuvant chemotherapy; C + CRT, adjuvant chemotherapy followed by chemoradiation; CI, confidence interval; CRT, chemoradiation; HR, hazards ratio; LN, lymph node; No., number of patients](CAM4-8-939-g002){#cam41967-fig-0002}

3.1. Cohort C {#cam41967-sec-0010}
-------------

The C group had a median follow‐up of 34.7 months (IQR 22.9‐54.6), and the C + CRT group had that of 39.7 months (IQR 26.7‐59.5). The median OS was 21.1 months (IQR 12.0‐34.7) for the C group and 23.4 months (IQR 15.6‐39.3) for the C + CRT group (log‐rank *P* \< 0.001). OS at 2 years was 48.8% for the C group and 53.1% for the C + CRT group.

A total of 2152 patients were matched. All variables were well balanced between these two groups (Table [1](#cam41967-tbl-0001){ref-type="table"}). The overall median follow‐up for the matched patients was 36.7 months (IQR 24.7‐54.5). The median OS was 20.0 months (IQR 11.5‐33.6) for the C group and 23.3 months (IQR 15.6‐39.2) for the C + CRT group (Figure [3](#cam41967-fig-0003){ref-type="fig"}; log‐rank *P* \< 0.001). OS at 2 years was 45.2% for the C group and 52.3% for the C + CRT group.

![Overall survival for cohort C after matching. *P* \< 0.001. C, adjuvant chemotherapy; C + CRT, adjuvant chemotherapy followed by chemoradiation](CAM4-8-939-g003){#cam41967-fig-0003}

3.2. Cohort CRT {#cam41967-sec-0011}
---------------

The CRT and C + CRT groups had a median follow‐up of 45.2 and 39.7 months, respectively. The median OS was 21.1 months (IQR 12.5‐36.0) for the CRT group and 23.4 months (15.6‐39.3) for the C + CRT group (log‐rank *P* \< 0.001). OS at 2 years was 46.2% and 53.1% for the CRT and C + CRT groups, respectively.

A total of 1774 patients were matched. All variables were well balanced (Table [2](#cam41967-tbl-0002){ref-type="table"}). The overall follow‐up was 40.2 months (IQR 26.0‐58.3). The CRT group had a median OS of 20.8 months (IQR 12.5‐34.7) and the C + CRT group had that of 23.4 months (IQR 16.0‐40.0). OS at 2 years was 46.6% for the CRT group and 52.5% for the C + CRT group (Figure [4](#cam41967-fig-0004){ref-type="fig"}; log‐rank *P* \< 0.001).

![Overall survival for cohort CRT after matching. *P* \< 0.001. CRT, adjuvant chemoradiation; C + CRT, adjuvant chemotherapy followed by chemoradiation](CAM4-8-939-g004){#cam41967-fig-0004}

4. DISCUSSION {#cam41967-sec-0012}
=============

To our knowledge, this is the first study to compare adjuvant C + CRT vs C or CRT alone for stage I‐II resected pancreatic cancer. This study suggests a survival benefit favoring the use of C + CRT for resected pancreatic cancer, specifically in cases of pathologically node‐positive disease.

The C + CRT cohort included over 70% patients with pathologically staged T3 and N1 disease, which are notably associated with worse prognosis.[20](#cam41967-bib-0020){ref-type="ref"}, [21](#cam41967-bib-0021){ref-type="ref"}, [22](#cam41967-bib-0022){ref-type="ref"} Despite this, the C + CRT still had better OS compared to the CRT alone cohort. The median OS was 23 months, which is comparable to or better than previously reported survival outcomes for adjuvant CRT alone.[5](#cam41967-bib-0005){ref-type="ref"}, [6](#cam41967-bib-0006){ref-type="ref"}, [7](#cam41967-bib-0007){ref-type="ref"}, [8](#cam41967-bib-0008){ref-type="ref"}, [9](#cam41967-bib-0009){ref-type="ref"}, [10](#cam41967-bib-0010){ref-type="ref"}

The use of adjuvant C in addition to CRT has only been investigated in a few studies.[6](#cam41967-bib-0006){ref-type="ref"}, [23](#cam41967-bib-0023){ref-type="ref"}, [24](#cam41967-bib-0024){ref-type="ref"}, [25](#cam41967-bib-0025){ref-type="ref"} RTOG 9704 delivered C before and after adjuvant CRT for resected pancreatic cancer. A large number of included patients had T3‐4N1 disease and positive surgical margins. Median OS was 17.1 months for fluorouracil and 20.5 months for gemcitabine.[25](#cam41967-bib-0025){ref-type="ref"} Likely due to the initial publication of RTOG 9704 in 2008, our logistic MVA results demonstrated that those diagnosed between 2008 and 2015 were more likely to receive C + CRT compared to those diagnosed between 2004 and 2007. A prior institutional study showed that delaying CRT until after \>1 cycle of adjuvant C is not associated with worse mortality when compared to adjuvant CRT only.[24](#cam41967-bib-0024){ref-type="ref"} Our study is the first report showing that delaying CRT until after 30‐180 days of adjuvant C may have survival benefits.

Our Cox MVA results (Table [3](#cam41967-tbl-0003){ref-type="table"}) showed that moderately or poorly differentiated tumors, larger tumor size, and pathologic N1 disease were adverse prognostic factors for mortality. This association is consistent with prior studies.[26](#cam41967-bib-0026){ref-type="ref"}, [27](#cam41967-bib-0027){ref-type="ref"}, [28](#cam41967-bib-0028){ref-type="ref"}, [29](#cam41967-bib-0029){ref-type="ref"}, [30](#cam41967-bib-0030){ref-type="ref"}, [31](#cam41967-bib-0031){ref-type="ref"}, [32](#cam41967-bib-0032){ref-type="ref"}, [33](#cam41967-bib-0033){ref-type="ref"}, [34](#cam41967-bib-0034){ref-type="ref"}, [35](#cam41967-bib-0035){ref-type="ref"} Older age, more medical comorbidities, low income, and positive surgical margins were also shown to be associated with worse mortality in our study, and this finding is also consistent with other reports.[36](#cam41967-bib-0036){ref-type="ref"}, [37](#cam41967-bib-0037){ref-type="ref"}, [38](#cam41967-bib-0038){ref-type="ref"}, [39](#cam41967-bib-0039){ref-type="ref"} In this study, treatment at academic facilities was an independent favorable prognostic factor for OS. This finding is consistent with prior analyses showing improved outcomes at high volume centers related to better surgical outcomes, which may explain why living in a rural area was associated with worse mortality.[40](#cam41967-bib-0040){ref-type="ref"}, [41](#cam41967-bib-0041){ref-type="ref"}, [42](#cam41967-bib-0042){ref-type="ref"} Although additional factors contributing to improved OS at academic facility may include patient self‐selection, higher socioeconomic status and/or performance status.

From our logistic MVA results, patients with pathologic T3‐4N1 diseases and positive surgical margins were more likely to receive C + CRT. A prior study has also shown that patients with a higher disease burden were more likely to receive adjuvant therapies.[43](#cam41967-bib-0043){ref-type="ref"}

In our study, the use of multiagent chemotherapy was not a favorable prognostic factor for survival. This finding is in contrast to theEuropean Study Group for Pancreatic Cancer‐4 (ESPAC‐4) trial. Despite including 61% of patients with positive surgical margins and 79% with N1 disease in the ESPAC‐4 trial, adjuvant gemcitabine combined with capecitabine significantly improved survival.[28](#cam41967-bib-0028){ref-type="ref"} In NCDB, multiagent chemotherapy was recorded as the first course, and it is possible that some chemotherapy regimens were changed during the course of treatments. This change in chemotherapy regimens is not recorded in NCDB, which may explain this discrepancy.

4.1. Limitations {#cam41967-sec-0013}
----------------

This study has a number of limitations, many of which are inherent to performing a retrospective review. Various potential prognostic factors, such as smoking and alcohol history, performance status, molecular tests, and the type and duration of chemotherapy, are not recorded by the NCDB. Outcomes such as local or distant recurrences, toxicity, and cancer‐specific survival were also unavailable. More than half of the CA 19‐9 values, an important prognostic factor for resectability and survival, were missing from this dataset and could not be included for propensity score matched analysis.[27](#cam41967-bib-0027){ref-type="ref"}, [44](#cam41967-bib-0044){ref-type="ref"}, [45](#cam41967-bib-0045){ref-type="ref"}, [46](#cam41967-bib-0046){ref-type="ref"}, [47](#cam41967-bib-0047){ref-type="ref"} The NCDB also does not include information on disease progression; therefore, this study cannot address the possibility of a patient received RT for progression of disease on chemotherapy. This limitation is inherent to all NCDB analyses and limit interpretation of our findings. Further, RT may have been palliative‐intent for a minority of the included patients based on site and dose of RT, but since both CRT and C‐CRT had similar numbers of patients receiving \<45 Gy, it is unlikely these patients would change the conclusions of this study. Since the NCDB is not a population‐based database, our findings may not be generalized to other patient populations.

Up to 79% of patients in RTOG 9704 experienced chemotherapy‐related toxicity. A meta‐analysis of adjuvant treatments for resected pancreatic adenocarcinoma also showed significant toxicity with the addition of chemotherapy to chemoradiation.[48](#cam41967-bib-0048){ref-type="ref"} It is possible that those patients who received C + CRT may have had a better initial performance status in order to tolerate the additional toxicity of chemotherapy, thus leading to better survival outcomes compared to those receiving C or CRT alone.[13](#cam41967-bib-0013){ref-type="ref"} This potential confounder may also explain the improved survival seen in other institutional studies.[6](#cam41967-bib-0006){ref-type="ref"}, [23](#cam41967-bib-0023){ref-type="ref"} However, it is unlikely that improved performance status was the only factor contributing to this overall survival benefit, since patients with node negative diseases would have also favored C + CRT in our study. In addition, no treatment interaction was seen with CDS or with age on Cox MVA in this study, nor were CDS or age predictors on logistic MVA for the receipt of C + CRT. Since all patients in our study underwent adjuvant therapies, the difference in performance status between the C + CRT and other regimens is unlikely to independently explain the survival benefits.

5. CONCLUSION {#cam41967-sec-0014}
=============

In summary, this analysis suggests improved survival for adjuvant C + CRT following resected pancreatic cancer with node‐positive disease. More studies may be warranted to investigate the benefit of adding adjuvant chemotherapy to CRT and the ideal sequencing of these regimens.
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